|
Emerging Mechanisms and Treatments for Depression (Supported by Alkermes)
Patrick Finley, PharmD, BCPP
Leslie Citrome, MD, MPH
Sunday, 4/7 at 11:30 AM
(Lunch Provided)
|
|
Changing the Treatment Landscape: Embracing Long-Acting Injectable Antipsychotics (Supported by Indivior, Alkermes)
Deanna Kelly, PharmD, BCPP; CPNP Member Activity Chair
Leslie Citrome, MD, MPH
Megan J. Ehret, PharmD, MS, BCPP Tuesday, 4/9 at 6:45 AM (Breakfast Provided)
|
|
Practical Strategies for Patient Follow-Up and Long-Term VMAT2 Inhibitor Treatment (Supported by Neurocrine Biosciences and Teva Pharmaceuticals)
Stephen Saklad, PharmD, BCPP; CPNP Member Activity Chair
Leslie Citrome, MD, MPH
Tuesday, 4/9 at 12:00 PM
(Lunch Provided)
|
  |
Treatment Goals: Journey of a Real Patient With Schizophrenia (Supported by Janssen)Michael Angelini, MA, PharmD |
 |
A New Path to Explore (Supported by Greenwich Biosciences)Barry Gidal, PharmD, FAES |
